SecBot SecBot
SECBOTREPLAY Home › Report › ABCL

ABCL · AbCellera announced a collaboration with Vertex Pharmaceuticals to…

AbCellera Biologics Inc. · 8-K filed Jul 29, 2026 at 11:38 ET

At the news

BULLISHIMPACT 6/10

8-K filed Jul 29, 2026 at 11:38 ET

AbCellera announced a collaboration with Vertex Pharmaceuticals to discover and develop multispecific T-cell engagers (TCEs) for autoimmune diseases. AbCellera receives $28 million in total upfront payments and is eligible for preclinical, development, regulatory, and commercial milestone payments plus tiered royalties. Vertex funds all R&D costs and has commercialization rights. This partnership validates AbCellera's TCE platform and provides non-dilutive capital, but no financial guidance or revenue impact was disclosed.

  • AbCellera announced a collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions.
  • AbCellera will receive $28 million in total upfront payments.
  • AbCellera is eligible to receive preclinical, development, regulatory, and commercial milestone payments, along with tiered royalties on net sales.
  • Vertex will fund all research and development costs and will have the right to develop and commercialize therapeutic multispecific antibodies resulting from the collaboration.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access